Stoke Therapeutics price target raised to $35 from $22 at Needham

Needham raised the firm’s price target on Stoke Therapeutics (STOK) to $35 from $22 and keeps a Buy rating on the shares. The company presented new zorevuneren OLE data in Dravet Syndrome, DS, at the 54th Child Neurology Society annual meeting yesterday, with new data that showed patients treated with zorevunersen had continued improvements in clinical outcomes through 3 years, and an analysis of patients in the OLE who received a similar dosing regimen as the ongoing Phase 3 trial continued to show improvements in the Vineland-3 at 2 years vs. a DS natural history study, the analyst tells investors in a research note. This new data increased the firm’s confidence in the long-term efficacy and durability of zorevunersen and the potential for significant differentiation over standard of care anti-seizure drugs for the treatment of DS, the firm added.